Page last updated: 2024-08-21

fluorobenzenes and Vascular Diseases

fluorobenzenes has been researched along with Vascular Diseases in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hata, M; Hirayama, A; Minami, K; Sezai, A; Takayama, T; Yoshitake, I	1
Page, RL; Slejko, JF; Sullivan, PW	1
Mikhailidis, DP; Paraskevas, KI; Veith, FJ	1
Balakumar, P; Kathuria, S; Mahadevan, N	1
Florkowski, CM; George, PM; Molyneux, SL	1

Reviews

1 review(s) available for fluorobenzenes and Vascular Diseases

Article	Year
Optimal statin type and dosage for vascular patients. Journal of vascular surgery, 2011, Volume: 53, Issue:3 Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Tolerance; Endovascular Procedures; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Pyrroles; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Diseases; Vascular Surgical Procedures	2011

Article

Year

Optimal statin type and dosage for vascular patients.

Journal of vascular surgery, 2011, Volume: 53, Issue:3

Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Tolerance; Endovascular Procedures; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Pyrroles; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Diseases; Vascular Surgical Procedures

2011

Other Studies

4 other study(ies) available for fluorobenzenes and Vascular Diseases

Article	Year
Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. The Annals of thoracic surgery, 2009, Volume: 88, Issue:5 Topics: Anticholesteremic Agents; Coronary Artery Bypass; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrimidines; Radiography; Rosuvastatin Calcium; Saphenous Vein; Sulfonamides; Ultrasonography; Vascular Diseases	2009
Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current medical research and opinion, 2010, Volume: 26, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Algorithms; C-Reactive Protein; Chemoprevention; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Up-Regulation; Vascular Diseases	2010
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Molecular and cellular biochemistry, 2013, Volume: 374, Issue:1-2 Topics: Anilides; Animals; Endothelium, Vascular; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nicotiana; Nicotine; Nitrates; Nitric Oxide; Nitric Oxide Synthase Type III; Nitrites; Oxidative Stress; PPAR gamma; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Smoking; Sulfonamides; Superoxides; Vascular Diseases	2013
Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Coenzymes; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Failure; Ubiquinone; Vascular Diseases	2008